ProShares Ultra NASDAQ Biotechnology
BIB
17 hedge funds and large institutions have $3.78M invested in ProShares Ultra NASDAQ Biotechnology in 2026 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 7 closing their positions.
203% more call options, than puts
Call options by funds: $2.27M | Put options by funds: $750K
58% more capital inflows, than outflows
Capital inflows: $525K | Capital outflows: $331K
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.11% more ownership
Funds ownership: 3.79% → 3.9% (+0.11%)
15% less funds holding
Funds holding: 20 → 17 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jump Financial
Chicago,
Illinois
|
+$457K |
| 2 |
Tower Research Capital (TRC)
New York
|
+$38.9K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$13.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.14K |
| 5 |
Harbour Investments
Madison,
Wisconsin
|
+$4.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$231K |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$50.4K |
| 3 |
Capital Investment Advisors
Atlanta,
Georgia
|
-$27.3K |
| 4 |
Truvestments Capital
Sarasota,
Florida
|
-$12.6K |
| 5 |
AIM
Axiom Investment Management
New York
|
-$5.04K |
BIB Hedge Fund Activity: Q3 2026 in Review
17 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2026, worth a combined $3.78M — up 21% from $3.13M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BIB and 4 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Jump Financial, adding an estimated $457K. The largest seller was Susquehanna International Group, cutting an estimated $231K.
- 17 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2026, down from 20 in Q2 2026.
- Funds reported $3.78M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2026, up 21% quarter-over-quarter.
- 4 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2026 and 7 closed out, a net change of -3 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2026 was Jump Financial, an estimated $457K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2026 was Susquehanna International Group, an estimated $231K sold.
Based on aggregated 13F filings for Q3 2026.